Respons to DAA among HIV/HCV co.infected people who inijet drug (PWID) in clinical practice.

Background: In Italy, the majority the HCV co-infections in HIV subjects occurred among PWID in the past years. PWID were often excluded from Interferon-based (IFN) regimens due to low adherence concerns, psychological and social fragility, high risk of adverse events and re-infection. Direct Acting Antivirals (DAA) have setted a new era in the HCV treatment, with the opportunity of a wide access and cure among highrisk populations including HIV/HCV co-infected PWID. Evaluation of safety and efficacy of DAA regimens in PWIDs is needed. We studied the response to DAA in a cohort of HIV/HCV seen for care in Italy, according to their current report of injecting drug use.